Amphastar Pharmaceuticals (AMPH) EV to FCF (2014 - 2026)

Amphastar Pharmaceuticals has reported EV to FCF for 13 years, with the latest figure at 13.3 in Q2 2026.

• On a quarterly basis, EV to FCF fell 60.18% year-over-year to 13.3 in Q2 2026; TTM through Jun 2026 was 3.72, a 50.11% decrease from a year earlier, with the FY2025 full-year figure at 7.75, down 13.63% from the prior year.
• EV to FCF was 13.3 for Q2 2026 at Amphastar Pharmaceuticals, down from 15.2 in the prior quarter.
• The five-year high for EV to FCF was 188.34 in Q4 2023, with the low at 590.24 in Q2 2022.
• Average EV to FCF over 5 years is 20.2, with a median of 39.05 recorded in 2024.
• The largest YoY upside for EV to FCF was 352.81% in 2022 against a maximum downside of 1856.07% in 2022.
• Over 5 years, EV to FCF stood at 131.49 in 2022, then surged by 43.24% to 188.34 in 2023, then tumbled by 50.58% to 93.08 in 2024, then sank by 58.95% to 38.21 in 2025, then plunged by 65.2% to 13.3 in 2026.
• The last three EV to FCF figures came in at 13.3 (Q2 2026), 15.2 (Q1 2026), and 38.21 (Q4 2025), per Business Quant data.